Allogeneic transplantation for myelofibrosis
نویسندگان
چکیده
منابع مشابه
Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Fifty-six patients, 10 to 66 years of age, with idiopathic myelofibrosis (IMF) or end-stage polycythemia vera or essential thrombocythemia received allogeneic hematopoietic cell transplants from related (n = 36) or unrelated (n = 20) donors. Forty-four patients were prepared with busulfan plus cyclophosphamide and 12 with total body irradiation plus chemotherapy. The source of stem cells was ma...
متن کاملAllogeneic hematopoietic cell transplantation for patients with myelofibrosis.
PURPOSE OF REVIEW Hematopoietic cell transplantation (HCT) offers potentially curative therapy for patients with myelofibrosis. What is the current status? RECENT FINDINGS Changes in transplant strategies allow offering HCT to patients who, because of age or comorbid conditions, were not considered transplant candidates in the past. The omission of high-dose total body irradiation, adjusting ...
متن کاملAllogeneic stem cell transplantation for myelofibrosis in 2012.
Myelofibrosis (MF) is a heterogeneous disease for which long-term, effective medical therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell transplant (AHSCT) in this population, many of whom are elderly, often provides a challenge with regard to the identification of suitable candidates, timing of transplantation in the disease course and choice of condition...
متن کاملImpact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
Allogeneic stem cell transplantation (ASCT) after reduced-intensity conditioning has become a reasonable treatment option for patients with advanced myelofibrosis. The role of characteristic molecular genetic abnormalities, such as JAK2V617F on outcome of ASCT, is not yet elucidated. In 139 of 162 myelofibrosis patients with known JAK2V617F mutation status who received ASCT after reduced-intens...
متن کاملIndications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis.
We enjoyed the recent authoritative review by Dr Tefferi on current management of patients with myelofibrosis.1 The article provides guidance for hematologists and oncologists in both academic settings and community-based practices. We would like to complement those recommendations by adding information on recent developments in allogeneic hematopoietic cell transplantation (HCT), at present th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Opinion in Hematology
سال: 2014
ISSN: 1065-6251
DOI: 10.1097/moh.0000000000000015